Yaɗuwar babban ƙwayar cutar B-cell lymphoma (DLBCL)-04

Martanin Farko Mai Ban Mamaki Game da Mista Monger: Maganin CD19/CD20 Mai Haɗaka Biyu Ya Kawo Sabon Fata Ga Masu Lalacewar DLBCL

Bayanin Majiyyaci 

Rodney Charles Monger, wani mutum mai shekaru 68 daga ƙasashen waje, an gano yana da cutar lymphoma mai girma na B-cell (DLBCL) shekaru uku da suka gabata. Ya nemi kulawa ta musamman a Asibitin Ciwon Daji na Tianjin a watan Agusta na 2025. An tabbatar da kamuwa da cutar lymphoma mai kama da B-cell mai kama da cutar germinal. An tabbatar da kamuwa da cutar Immunohistochemistry sosai ga CD20, CD19, da CD10, tare da yawan bayyanar Bcl-6, Bcl-2 (70%+), da c-MYC (60%+). Gwajin kwayoyin halitta ya nuna sake fasalin BCL2 ta hanyar FISH da maye gurbi a cikin kwayoyin halittar EZH2, KMT2D, TNFRSF14, NRAS, da TPMT - alamun sun yi daidai da yanayin da ke da haɗari, mai tsanani.

Tafiyar Jiyya ta Farko 

A watan Agusta na 2025, Mista Monger ya karɓi maganin pola tare da maganin hana BTK da lenalidomide. Daga nan aka yi masa maganin cutar kansa ta FC (fludarabine + cyclophosphamide). Duk da waɗannan ƙoƙarin, cutar ta ci gaba da zama mai tsauri, wanda hakan ya sa ƙungiyar likitoci ta ba da shawarar maganin ƙwayoyin cuta na Bioocus guda biyu na CD19/CD20 CAR-T.

A ranar 8 ga Satumba, 2025, Mista Monger ya karɓi ƙwayar halittar CAR-T ta CD19/CD20 mai ɗauke da ƙwayoyin cuta. Abin mamaki, ya fuskanci cutar. babu alamun sakin cytokine (CRS)kuma babu wata cuta da ke da alaƙa da ƙwayoyin cuta masu illa ga garkuwar jiki (ICANS)— wani magani mai santsi bayan an yi masa allura wanda ya ba shi damar kasancewa cikin kwanciyar hankali da kyakkyawan fata tun daga rana ta farko.

Faɗaɗa ƙwayoyin CAR-T: Mai sauri da ƙarfiSa ido kan jinin da ke kewaye ya nuna faɗaɗa ƙwayoyin CAR-T mai ban sha'awa, yana tabbatar da kyakkyawan tsari da yaduwa:

• D4 bayan jiko(Satumba 12): Kwayoyin CAR19+ sun kasance 0.50% na ƙwayoyin CD3+ T (ƙimar cikakkiyar 6.04 × 10⁷/L); Kwayoyin CAR20+ 0.41% (4.96 × 10⁷/L).
• D7(Satumba 15): CAR19+ ya tashi zuwa 1.68% (1.40 × 10⁷/L); CAR20+ zuwa 1.63% (1.36 × 10⁷/L).
• D10(Satumba 18): An kai CAR19+ Kashi 43%na ƙwayoyin CD3+ T (cikakken ƙima 3.13 × 10⁸/L); An kai CAR20+ Kashi 32.74%(cikakken ƙima 3.26 × 10⁸/L).

Tsarin kwararar jini ya kuma nuna daidaiton rarrabawa a cikin ƙananan CD4+ da CD8+, tare da ƙarfin bayyanar CAR guda biyu. Lanƙwasa masu motsi sun nuna wani matakin faɗaɗawa mai faɗi, yana nuna cewa ƙirar CD19/CD20 guda biyu ta haɓaka juriya da haɓaka CAR-T yadda ya kamata a cikin jiki.

Matsayin Yanzu da Kulawa Mai Tallafi 

A sabon bincike (D10), Mista Monger ya ci gaba da yin aiki mai kyau a asibiti. Yana shan maganin da aka tsara masa ta hanyar amfani da acyclovir, sulfamethoxazole, orelabrutinib, lenalidomide, da kuma magungunan tallafi, tare da sa ido akai-akai kan yawan jini, aikin hanta da koda, da kuma alamun kumburi kamar yadda aka tsara a tsarin fitar da shi.

Tawagar Bioocus ta ba da cikakken tallafi, wanda ya mayar da hankali kan marasa lafiya a duk tsawon lokacin: masauki mai daɗi, abinci mai gina jiki, taimakon sufuri, da kuma shawarwari kan tunani ga Mista Monger da iyalinsa. Wannan tsarin ya taimaka masa ya mai da hankali sosai kan murmurewa.

Saƙon Bege 

Shari'ar Mr. Monger ta nuna misali na yiwuwar sauya yanayin maganin Bioocus dual CD19/CD20 CAR-T ga marasa lafiya da suka sake dawowa/rage ƙarfin DLBCL. Faɗaɗa ƙwayoyin CAR-T cikin sauri da ƙarfi ba tare da mummunan guba ba yana nuna kyakkyawan yanayin aminci na samfurin da kuma ƙarfin aikin hana ƙari mai ƙarfi - har ma a cikin tsofaffi marasa lafiya waɗanda ke da halayen ƙwayoyin cuta masu haɗari.

Muna alfahari da tallafawa marasa lafiya kamar Mr. Monger a kan tafiyarsu ta komawa ga lafiya. Labarai irin nasa suna ƙarfafa alƙawarinmu na samar da sabbin hanyoyin magance matsalolin ƙwayoyin halitta tare da kulawa ta musamman.

Ana bayar da rahoton wannan lamari ne da izinin majiyyaci. Sakamakon na iya bambanta; Sakamakon CAR-T ya dogara ne akan ilimin halittar cututtuka daban-daban da kuma abubuwan asibiti. Don ƙarin bayani ko don bincika zaɓuɓɓukan magani, da fatan za a ziyarci shafinmu na CAR-T Therapy for Non-Hodgkin Lymphoma.